EVAX

In the tech narratives of 2026, if you are still just talking about large language models themselves, you have probably missed the core plot. I'm told that the most aggressive capital in Silicon Valley and Wall Street is currently flooding into the granular, underlying hardware nodes that keep these massive models running—and they are bringing heavy leverage with them.

This matters because as AI computation shifts increasingly toward highly customized silicon, the entire hardware supply chain is undergoing an unprecedented re-architecture. Over the past few years, capital could effortlessly win just by blindly buying up top-tier aggregators. But now, the real bottlenecks are moving toward niche components like high-bandwidth memory (HBM), advanced testing, optical transceivers, and magnetoresistive RAM (MRAM).

Just look at the aggressive moves by SK Hynix (SKHY.US) to see the scale of this shift. As the behemoth currently monopolizing the lion's share of the global high-bandwidth memory market, the company commanded a massive 58% revenue market share in HBM in the first quarter of 2026. To get closer to its primary customers, SK Hynix officially broke ground in August 2026 on a sprawling advanced memory packaging facility in Indiana, fueled by a total investment exceeding USD 4 billion. Furthermore, CEO Kwak Noh-Jung boldly predicted that due to the shift toward custom AI memory, the global memory chip shortage could drag on until the end of 2030. That kind of multi-year visibility is exactly the certainty the capital markets crave right now.

But the market's appetite for risk is never fully satiated. For active traders who simply cannot wait for HBM4E mass production in 2029, hunting for highly elastic, single-node bottlenecks has become the new normal. The truth, as usual, is more complicated: plain-vanilla equity positions can no longer satisfy the market's hunger for volatility.

We are now seeing the emergence of single-stock leveraged ETFs specifically targeting testing equipment, optical components, and specialty memory. Take Leverage Shares 2x Long AEHR Daily ETF (AEHG.US), which tracks Aehr Test Systems, and Leverage Shares 2x Long COHR Daily ETF (COHH.US), tracking Coherent Corp. These two Cboe-listed instruments offer traders a daily 2x amplified exposure to their respective underlying stocks. Aehr dominates the crucial wafer-level burn-in equipment for silicon carbide and silicon photonics, while Coherent is an absolute powerhouse in optical communications. The frenzy surrounding these leveraged ETFs is essentially a high-stakes bet on optical interconnects and chip yield testing as the absolute choke points in the AI compute network.

Also swept up in this leverage game is Tradr 2X Long MRAM Daily ETF (MRAX.US), a trading tool offering double the daily performance of Everspin Technologies. As processor chips grow exponentially more powerful, MRAM—a persistent memory designed to retain data even after power loss—is being touted as a dark horse component in next-generation, high-reliability computing architectures. Wall Street's logic here is brutally simple: as long as AI chips keep pushing the physical limits of power consumption and heat dissipation, the premium on these specialty hardware pieces will multiply.

And yet... right at the moment when the hardware arms race is at its fiercest, someone is trying to use all this compute to re-architect the human biological system. Evaxion (EVAX.US) is the anomaly in this group. As a tech-bio company, Evaxion utilizes its proprietary AI-Immunology platform to decode the human immune system, attempting to develop novel vaccine candidates for cancer and infectious diseases. Following its Q2 2026 earnings call in August, the investment bank JonesTrading maintained a Buy rating and a USD 10 price target on the stock. While most of the world treats AI as a tool to make enterprise software incrementally more efficient, Evaxion is trying to use it to solve actual life-and-death equations.

My view is that we are entering the most dangerous, yet fascinating, deep waters of AI infrastructure investing. From tens of billions of dollars poured into cross-border semiconductor mega-fabs, to single-stock ETFs violently swinging with 2x leverage intraday, the market's greed has drilled all the way down to the nerve endings of the supply chain. Whoops! Trying to perfectly time every hardware cycle in this era of customized compute is like dancing on the edge of a knife. Good luck with that.

This article does not constitute investment advice.